Complement component 3 inhibition by an antioxidant is neuroprotective after cerebral ischemia and reperfusion in mice.
Jiwon Yang, Hye-Na Ahn, Minsun Chang, Purnima Narasimhan, Pak H Chan, Yun Seon Song
Index: J. Neurochem. 124(4) , 523-35, (2013)
Full Text: HTML
Abstract
Oxidative stress after stroke is associated with the inflammatory system activation in the brain. The complement cascade, especially the degradation products of complement component 3, is a key inflammatory mediator of cerebral ischemia. We have shown that pro-inflammatory complement component 3 is increased by oxidative stress after ischemic stroke in mice using DNA array. In this study, we investigated whether up-regulation of complement component 3 is directly related to oxidative stress after transient focal cerebral ischemia in mice and oxygen-glucose deprivation in brain cells. Persistent up-regulation of complement component 3 expression was reduced in copper/zinc-superoxide dismutase transgenic mice, and manganese-superoxide dismutase knock-out mice showed highly increased complement component 3 levels after transient focal cerebral ischemia. Antioxidant N-tert-butyl-α-phenylnitrone treatment suppressed complement component 3 expression after transient focal cerebral ischemia. Accumulation of complement component 3 in neurons and microglia was decreased by N-tert-butyl-α-phenylnitrone, which reduced infarct volume and impaired neurological deficiency after cerebral ischemia and reperfusion in mice. Small interfering RNA specific for complement component 3 transfection showed a significant increase in brain cells viability after oxygen-glucose deprivation. Our study suggests that the neuroprotective effect of antioxidants through complement component 3 suppression is a new strategy for potential therapeutic approaches in stroke.© 2012 International Society for Neurochemistry.
Related Compounds
Related Articles:
2011-02-01
[Anticancer Res. 31(2) , 487-94, (2011)]
2015-03-01
[J. Interferon Cytokine Res. 35(3) , 143-56, (2015)]
2015-01-01
[PLoS ONE 10 , e0136450, (2015)]
2014-12-01
[J. Pharmacol. Exp. Ther. 351(3) , 568-75, (2014)]
2013-12-15
[Toxicol. Appl. Pharmacol. 273(3) , 508-15, (2013)]